Gabapentin Use in Benzodiazepine Dependence and Detoxification

Dear Edi tor:
Once pa tients be come de pend ent on ben zo di azepines, dis con tinu ing them of ten proves vex ing. De toxi fi ca tion ends up be ing pro longed or un suc cess ful due to with drawal or re-emergent anxiety (1) , as well as to the need for an ex ternal source of con trol (2) . Ga bap en tin is a novel an ti con vul sant, struc tur ally analogous to gamma-aminobutyric acid (GABA), that pro motes GABA re lease via un known mecha nisms (3) . It has been re ported help ful in the man agement of pain syn dromes (4), anxi ety (5) (6) (7) , and al co hol with drawal (8) . We pres ent a case wherein de toxi fi ca tion from ben zo di azepines was aided by the use of ga bap en tin; there have been no pre vi ous simi lar re ports.
Mrs A was a 49-year-old woman with a 7-year his tory of con tinu ous de pendence on 12 to15 mg of al pra zo lam daily. Tol er ance, with drawal, and loss of control char ac ter ized her use, with marked in ter fer ence in her work and home life. Her ben zo di azepine de pend ence was com pli cated by Fiorinal-C½ and diphen hy dramine abuse. Com pound ing mat ters was a his tory of re cur rent panic and gen er al ized anxi ety, fre quent depres sive epi sodes with sui ci dal ity, and so ma ti za tion. She en tered hos pi tal af ter a sui cide at tempt in which she took 60 to 75 mg of al pra zo lam. De spite mul ti ple so matic com plaints, her physi cal status was un re mark able, with nor mal re nal func tion.
She was con tin ued on her pre vi ous paroxet ine at 20 mg daily. Al pra zo lam, barbi tu rates, opi ates, and an ti his ta mines were stopped. A clo naze pam ta per was started at 2 mg twice daily, with dose as needed for break through with drawal or marked anxi ety. On 1 mg of clo naze pam daily her ta per stalled; over whelm ing anxi ety, tremor, and af fec tive in sta bil ity pre vented fur ther dose re duc tion. Due to her in sta bil ity and con tin ued ben zo diazepine use, she was de clined en try into resi den tial ad dic tion treat ment. She refused car be mazepine be cause of po tential side ef fects. She in stead started on 200 mg of ga bap en tin 3 times daily. Initially as her symp toms of anxi ety, tremor, and af fec tive la bil ity rap idly decreased, she de scribed ga bap en tin as "feel ing like al pra zo lam." Clo naze pam was then ta pered off. Within 3 weeks of ad mis sion, she was benzodiazepinefree. The sub jec tive, alprazolam-like effect faded, but anx ious symp toms remained con trolled, with lit tle crav ing for ben zo di azepines or other sub stances, includ ing ciga rettes. She de nied any adverse ef fects from the medi ca tion, ex cept for short-term se da tion. The to tal daily dose of ga bap en tin re mained low (600 mg daily). Off ben zo di azepines, her men tal state im proved, al low ing discharge from hos pi tal and com mencement of out pa tient ad dic tion treat ment. Two months later, she re mained ab sti nent.
Car be mazepine has been used in ben zodi azepine de toxi fi ca tion (1), but its poten tial for ad verse ef fects ne ces si tates close moni tor ing and labo ra tory test ing. These con cerns pre cluded its use in this case. Al ter na tively, pro longed ben zo diazepine ta pers of ten fail (1, 9) or can obstruct en try into ad dic tion treat ment. In this case, the ad di tion of ga bap en tin appeared to ease the ben zo di azepine detoxi fi ca tion pro cess ap pre cia bly, short en ing over all with drawal time while side step ping com monly en countered prob lems. Ga bap en tin has a relatively be nign side-effect pro file with few known drug in ter ac tions, a wide thera peu tic win dow, does not re quire blood moni tor ing, and is not me tabolized by the liver (3, 4) . Its use may thus of fer a rea son able al ter na tive, be yond the cur rently avail able op tions, for withdraw ing benzodiazepine-dependent pa tients. mass in dex [BMI]: weight [89 kg] / height [1.6m 2 ] = 34.8). A 42-year-old woman with a 26-year his tory of chronic re cur rent de pres sive epi sodes pre sented with a past par tial or un sat is fac tory response to vari ous an ti de pres sant drug treat ments and com bi na tion or aug menta tion strate gies. These in cluded the tricyc lic an ti de pres sants (TCAs) imi pramine and clo mi pramine; also used were par oxet ine, ser tra line, moclobe mide, phe nelz ine, lith ium, T3, psycho ther apy, and typi cal an tipsy chot ics (thio ri daz ine and pi mozide). It is, however, very im por tant to note that she did not com ply with some of these treatments: be cause she no ticed weight gain, she did not agree to dose in creases and also dis con tin ued medi ca tions be fore reach ing an op ti mum dose, al though at cer tain pe ri ods in her life, clini cal improve ment ap peared to be par tially sat is fac tory.
She was com menced on fluoxet ine because this se lec tive se ro tonin re up take in hibi tor (SSRI) is re ported to de crease ap pe tite and can cause weight loss (1, 2) . Her ini tial 17-item Ham il ton De pres sion Rat ing Scale (HDRS) score was 34. Fluoxet ine was ini ti ated at a dose of 20 mg daily, which was gradu ally in creased over 8 weeks to the maxi mum tol er ated dose of 50 mg daily. There was minimum weight loss (1.5 kg) over this time, and the clini cal im prove ment (de pressive psy cho pa thol ogy) was mild (HDRS score, 27). There fore, we de cided to augment fluoxet ine with topi ra mate, for the fol low ing 3 rea sons: topi ra mate is a po ten tial mood sta bi lizer with a pos si ble an ti de pres sant ef fi cacy (3); there is no po ten tial phar ma coki netic in ter ac tion be tween topi ra mate and fluoxet ine, because they are me tabo lized via dif fer ent liver CYP-450 en zymes (1, 4) ; and the obe sity re mained a medi cal prob lem that pos si bly con trib uted to the pa ti ent's depres sion, while topi ra mate has a de sirable side ef fect of weight loss, even for weight gain in duced by psy cho tropic drugs (4). The pa tient was com menced on topi ra mate 25 mg at bed time, and the dose was gradu ally in creased up to 250 mg daily to re sponse over 14 weeks. There was sig nifi cant im prove ment of de pres sive psy cho pa thol ogy at week 14 (HDRS score, 8) . It is in ter est ing to note that the clear and sig nifi cant im provement of de pres sive psy cho pa thol ogy coin cided with sig nifi cant re duc tion in the pa ti ent's weight at week 14 (weight loss was grad ual, with a to tal loss of 30 kg and a new weight of 59 kg). She re ported no sig nifi cant change in eat ing pat tern and hab its or in food con sump tion. She did not feel tired or fa tigued but, rather, more en er getic and ac tive, and she started ex er cis ing to main tain the weight loss. Re ported side ef fects in cluded mild hand tremor, se da tion, and nau sea.
The pre cise mecha nism of ac tion of the an ti de pres sant ef fi cacy of fluoxet ine plus topi ra mate and the mecha nism of ac tion of the ac cel er ated aug men ta tion of the weight loss re main un clear. However, fluoxet ine ap pears to de crease appe tite and weight, which may be re lated to its ac tions on 5-HT 2C re cep tors (5) . It is pos si ble that topi ra mate may di rectly or in di rectly (via first or sec ond mes senger sys tems) aug ment 5-HT 2C re cep tor func tion and fur ther con trib ute to weight loss. Un for tu nately, a Med line search failed to yield any data on the serotoninreceptor-bind ing pro file of topi ra mate that would con firm our hy pothe sis. It is also pos si ble that do pa mine, nora drenaline, or glu ta mate sys tems may be involved in the ac cel er ated weight-loss mecha nism of ac tion ob served with this com bi na tion. Such a com bi na tion may nev er the less be con sid ered in a se quential way for pa tients with re frac tory depres sion who have a BMI of over 30 or who are clini cally judged to be at a risk of de vel op ing medi cal dis or ders due to obe sity. Be cause this is a case re port, the out come can not be gen er al ized un til further con fir ma tory con trolled stud ies have been con ducted.
